Articles from Auron Therapeutics Inc.

AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC models

NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will present updated preclinical data from its lead program, AUTX-703, during a poster session at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.

NEWTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced the appointment of Glenn Goddard as Chief Financial Officer. Mr. Goddard is a seasoned biopharma executive with more than 25 years of leadership experience in biotechnology companies, including managing financial and business operations, significant fund-raising and investor relations experience, and corporate strategic planning.

Initiating Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025

Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present new preclinical data from its lead program AUTX-703 during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition from December 7-10, 2024 in San Diego, CA.

Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models

NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present updated preclinical data from its lead program during a poster session at the 31st Annual Prostate Cancer Foundation (PCF) Annual Scientific Retreat from October 24-26, 2024 in Carlsbad, CA.

NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present updated preclinical data from its lead program during a poster session at the 36th EORTC-NCI-AACR (ENA) Symposium from October 23-25, 2024 in Barcelona, Spain.

Company showcases property-based design and optimization of orally bioavailable degraders targeting KAT2A/B

NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced an oral presentation on the company’s proprietary AURIGIN™ platform at the AI in Biomedicine Keystone Symposia held May 1-3, 2024.

Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models

NEWTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present an overview of its proprietary AURIGIN™ platform and the first preclinical data from its lead program during two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2024.

AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy

Dr. Vicky Richon, Appointed to Board of Directors; Chris Guiffre Appointed President and Chief Operating Officer

Advisory Board includes recognized physicians, clinicians and scientists with deep expertise spanning multi-omic platforms, translational biology, drug discovery and clinical development